Cardiac Denervation Ablation Strategy for Severe Sinus Bradycardia
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Sinus Bradycardia
- Sponsor
- China National Center for Cardiovascular Diseases
- Enrollment
- 88
- Locations
- 1
- Primary Endpoint
- Number of patients with postoperative recurrence of bradycardia symptoms
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a prospective clinical observation and registration study. The investigator aimed to evaluate the efficacy and safety of cardiac denervation ablation as a treatment strategy for severe sinus bradycardia.
Detailed Description
Severe sinus bradycardia (SSB) is a common clinical condition that can lead to symptoms such as dizziness, fainting, and even cardiac arrest, posing a serious threat to patients' health and life. The causes of SSB vary: in elderly patients, SSB is often caused by ischemia and degenerative changes in the sinoatrial node, while in younger patients, it is often due to abnormal elevation of vagal nerve tone resulting in slowed heart rate and weakened myocardial contractility. Although implanting a pacemaker can effectively alleviate SSB bradycardia, the incidence of pacemaker electrode-related complications (such as electrode displacement, insulation layer rupture, lead infection, and fracture) is not low. Moreover, the impact of pacemaker implantation on patients' quality of life and the economic burden of regular pacemaker battery replacement impose significant psychological and financial burdens on patients, especially young patients. Clearly, for young SSB patients, if the abnormally elevated vagal nerve tone can be continuously reduced, it would be more effective in treating bradycardia and avoiding pacemaker implantation, which has significant social and economic value. The investigators has pioneered the technique of cardiac denervation ablation, which can modulate the autonomic nervous tone of the heart and is used to treat autonomic nervous system-related diseases. In a preliminary exploratory study involving 6 SSB patients, investigators found that cardiac denervation ablation for SSB can reduce vagal nerve tone, increase sinus heart rate, and effectively alleviate bradycardia symptoms, thus avoiding the need for pacemaker implantation. Therefore, based on the preliminary work, this project aims to conduct a prospective observational study and establish a registry. SSB patients who meet the indications for pacemaker implantation will be selected to evaluate the efficacy and safety of cardiac denervation ablation for SSB, its impact on quality of life, and the effectiveness of avoiding pacemaker implantation. The project will establish standardized surgical strategies and protocols for cardiac denervation ablation for SSB, summarize experiences, and lay the foundation for the clinical promotion and guideline revision of catheter ablation for SSB.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Sinus bradycardia and pacemaker implantation indication: long interval with mean heart rate \<45 bpm or 3s recorded within 6 months before inclusion;
- •Negative atropine test: sinus heart rate\> 90bpm after atropine injection
- •SSB related symptoms: dizziness, palpitations, fatigue, amaurosis, syncope, etc.
- •Age ≥18 and \<60 years old;
- •The patient has agreed to participate in this trial and has signed the informed consent form.
Exclusion Criteria
- •Previous history of atrial arrhythmia ablation or surgical procedure;
- •Structural heart disease, chronic liver and kidney dysfunction, diabetes mellitus, neurological diseases.;
- •Drug-related SSB;
- •presence of left atrial thrombus;
- •Pregnant women.
Outcomes
Primary Outcomes
Number of patients with postoperative recurrence of bradycardia symptoms
Time Frame: 12 months after ablation procedure
Symptoms such as chest tightness, suffocation, amaurosis, syncope with cardiac arrest with mean heart rate \<45bpm or ≥3s on 12-lead ECG or Holter
Secondary Outcomes
- Changes in minmum heart rate(3, 6, 12 months after ablation procedure)
- Changes in quality of life measured by Medical Outcomes Study 36- Item Short Form Health Survey (SF-36)(3, 6, 12 months after ablation procedure)
- The result of the atropine test(12 months after ablation procedure)
- Changes in quality of life measured by EuroQol Five Dimensions Questionnaire Visual Analogue Scale (EQ VAS)(3, 6, 12 months after ablation procedure)
- Changes in mean heart rate(3, 6, 12 months after ablation procedure)
- Changes in deceleration capacity(3, 6, 12 months after ablation procedure)